Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC Study) Population
Sponsor: Finnish Institute for Health and Welfare
Listed as NCT00342992, this observational or N/A phase trial focuses on Cancer and Diabetes Mellitus and remains completed. Sponsored by Finnish Institute for Health and Welfare, it has been updated 23 times since 1995, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)The ATBC study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with a-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers among male smokers. Between 1985 and 1988, 29,133 men ages 50 to 69 years, who smoked at least five cigarettes per day, were recruited from southwestern Finland. Participants were randomly assigned to receive either a-tocopherol as dl-a-tocopheryl acetate (50 mg/day), beta-carotene as all-trans-beta-carotene (20 mg/day), both supplements, or placebo capsules for 5-8 years (median 6.1 years) through April 30, 1993. Post-intervention follow-up has continued through the Finnish Cancer Registry and other national registries, and epidemiological analyses continue to be conducted.
The ATBC study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with a-tocopherol, beta-carotene, or both would reduce the incidence of lung or other cancers among male smokers. Between 1985 and 1988, 29,133 men ages 50 to 69 years, who smoked at least five cigarettes per day, were recruited from southwestern Finland. Participants were randomly assigned to receive either a-tocopherol as dl-a-tocopheryl acetate (50 mg/day), beta-carotene as all-trans-beta-carotene (20 mg/day), both supplements, or placebo capsules for 5-8 years (median 6.1 years) through April 30, 1993. Post-intervention follow-up has continued through the Finnish Cancer Registry and other national registries, and epidemiological analyses continue to be conducted.
Status Flow
Change History
23 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Oct 2020 — Jan 2021 [monthly]
Completed
-
Sep 2020 — Oct 2020 [monthly]
Completed
▶ Show 18 earlier versions
-
Mar 2020 — Sep 2020 [monthly]
Completed
-
Feb 2020 — Mar 2020 [monthly]
Completed
-
Dec 2019 — Feb 2020 [monthly]
Completed
-
Oct 2019 — Dec 2019 [monthly]
Completed
-
Aug 2019 — Oct 2019 [monthly]
Completed
-
Jun 2019 — Aug 2019 [monthly]
Completed
-
May 2019 — Jun 2019 [monthly]
Completed
-
Apr 2019 — May 2019 [monthly]
Completed
-
Feb 2019 — Apr 2019 [monthly]
Completed
-
Oct 2018 — Feb 2019 [monthly]
Completed
-
Sep 2018 — Oct 2018 [monthly]
Completed
-
Jul 2018 — Sep 2018 [monthly]
Completed
-
Jun 2018 — Jul 2018 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Completed NA
-
May 2017 — Jun 2017 [monthly]
Completed NA
-
Jan 2017 — May 2017 [monthly]
Completed NA
First recorded
Mar 1995
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Finnish Institute for Health and Welfare
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .